Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY2780301 + paclitaxel
- Development stage
- Discontinued
- Lead developer
- Eli Lilly
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
LY2780301 is a dual inhibitor of p70 ribosomal protein S6 kinase (p70S6K) and protein kinase B (AKT), both key components of the PI3K/AKT/mTOR signaling pathway, which is frequently activated in HER2-negative breast cancer. Paclitaxel is a well-established microtubule-stabilizing chemotherapeutic agent. The combination of LY2780301 with weekly paclitaxel has been investigated for the treatment of hormone-resistant HER2-negative advanced breast cancer, with preliminary evidence suggesting feasibility and efficacy in both the overall population and patients with activation of the PI3K/AKT pathway[1][2][3]. The recommended phase II dose was determined as LY2780301 500 mg once daily plus weekly paclitaxel 80 mg/m²[2].
- Other names
- LY2780301 and paclitaxelLY-2780301 and paclitaxelLY 2780301 and paclitaxelpaclitaxel plus LY2780301
02
Targets
RPS6KB1 (Ribosomal protein S6 kinase beta-1)TUBB (Tubulin (alpha and beta subunits))AKT (RAC-alpha serine/threonine-protein kinase)
Beyond the preview
Go deeper on LY2780301 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY2780301 + paclitaxel.